Shares of Acorda Therapeutics (ACOR +2.4%) get a boost with an upgrade from Citi analyst Yaron...

|About: Acorda Therapeutics, Inc. (ACOR)|By:, SA News Editor

Shares of Acorda Therapeutics (ACOR +2.4%) get a boost with an upgrade from Citi analyst Yaron Weber to Buy from Hold who says the share price now reflects competitive market factors for the drugmaker. He forecasts sales of the firm's Ampyra to increase to $204M in 2011, just off the firm's target of $205M-$230M.